Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2005-09-13
2005-09-13
Nguyen, Dave Trong (Department: 1635)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S320100, C435S325000, C435S252300, C424S093200, C536S023200, C536S024100
Reexamination Certificate
active
06943026
ABSTRACT:
Compositions for targeting expression of a gene such as an antitumor gene may contain a first nucleic acid construct in which expression of a first gene is controlled by a first promoter whose function is suppressed in non-tumor cells, and a second nucleic acid construct in which expression of a second gene for down-regulating the first gene in non-tumor cells is controlled by a second promoter that is up-regulated in non-tumor cells. The second promoter may be regulated by means of p53 binding, targeting expression of the first gene to cells in which p53 down-regulation of expression is disrupted, e.g. cells in which p53 is mutated. The first promoter may be one which is unregulated in tumor cells, for example the Hsp70 promoter which is upregulated in mutant p53 tumor cells. A suitable antitumor agent in thymidine kinase.
REFERENCES:
patent: 5700657 (1997-12-01), Beaudry et al.
patent: 6004941 (1999-12-01), Bujard et al.
patent: 195 02 584 (1995-03-01), None
patent: WO 93/15769 (1993-08-01), None
patent: WO 94/23046 (1994-10-01), None
patent: WO 94/29442 (1994-12-01), None
patent: WO95/16771 (1995-06-01), None
patent: WO 95/19367 (1995-07-01), None
Gura (Science 278:1041-1042, Nov. 7, 1997).
Viewig (Cancer Invest. 13(2): 193-201 (1995)).
Le Beau et al (Nature 316(6031):826-828, 1985).
Deb et al J. Virol. 66(10): 6164-6170, 1992.
Blau et. al., Gene Therapy- A Novel form of drug delivery; 1995, The New England Journal of Medicine, vol. 333:1204-1207.
Crystal, Transfer of Genes to Humans: Early Lessons and Obstacles to Success; 1995, Science vol. 270: 404-410.
Miller et. al., Targeted vectors for gene therapy, 1995;FASEB , vol. 9:190-199.
Orkin et. al.; Report and Recommedations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 1995, pp. 1-41.
Deb et al J. Virol. 66(10):6164-6170.
Viewig (Cancer Invest. 13(2): 193-201 (1995).
Le Beau et al (Nature 316(6031): 826-828, 1985).
Yamaguchi et al (Eur. J. Biochem. (1994) 221: 227-237).
Symonds et al (J. Virol. (1991) 65(10): 5417-5424).
Ohashi et al (Genomics (1995) 30(2): 406-407).
Rotter et al (Mol. Cell. Biol. (1984) 4(2):383-385).
Deuschle, Tetracycline-Reversible Silencing of Eukaryotic Promoters; 1995, Molecular and Cellular Biology; 1907-1914.
I. Verma et. al., Gene therapy-promises, problems and prospects, 1997, Nature vol. 389:239-242.
Ross et. al., Gene therapy in the United States: A five-year status report, 1996; human Gene Therapy 7:1781-1790.
Fick et al., The Extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytoxicity in vitro, 1995; Proc. Natl. Acad. Sci. vol. 92: 11071-11075.
Beck et. al. , TheThymidine Kinase/Ganciclovir-Mediated “Suicide” Effect Is Variable In Different Tumor Cells, 1995; Human Gene Therapy 6: 1525-1530.
Orkin et. al.; Report and Recommedations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 1995.
Deuschle, Ulrich et al., (1995) “Tetracycline-Reversible Silencing of Eukaryotic Promoters”, Molecular and Cellular Biology, vol. 15, No. 4, p. 1907-1914.
Pavletich, Nikola et al., (1993) “The DNA-Binding Domain of p53 Contains The Four Conserved Regions And The Major Mutation Hot Spots”, Genes & Development, pp. 2557-2564.
Pescini, Rosanna et al. (1994) “Inducible Inhibition of Eukaryotic Gene Expression”, Biochemical and Biophysical Research Communications, vol. 202, No. 3, pp. 1664-1667.
Pitts, John D. (1994) “Cancer Gene Therapy: A bystander Effect Using The Gap Junctional Pathway” Molecular Carcinogenesis, vol. 11 pp 127-130.
Selvakumaran, Muthu et al. (1994) “Immediate Early Up-Regulation of bax Expression by p53 But Not TGFβ1: A Paradigm For Distinct Apoptotic Pathways”, Oncogene, vol. 9, No. 6, pp. 1791-1798.
Shiio, Yuzuru et al. (1993) “Indentification of A DNA Element That Can Enhance p53-Mediated Transactivation”, Oncogene, vol. 8, NO. 8, pp. 2059-2065.
Takebe, Yutaka et al. (1988) “SRα Promoter: An Efficient And Versatile Mammalian cDNA Expression System Composed of the Simian Virus 40 Early promoter and the R-U5 Segment of Human T-Cell Leukemia Virus Type 1 Long Terminal Repeat”, Molecular and Cellular Biology, vol. 8, No. 1, pp. 466-472.
Tsutsumi-Ishii, Yuko et al. (1995) “Response of Heat Shock Element Within The Human HSP70 Promoter To Mutated p53 Genes”, Cell Growth & Differentation, vol. 6, No. 1, pp. 1-8.
Balmain Allan
Zhu Jing de
Cyclacel Limited
DeConti, Jr. Giulio A.
Kanik Cynthia L.
Lahive & Cockfield LLP
Nguyen Dave Trong
LandOfFree
Antitumour vector constructs and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antitumour vector constructs and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antitumour vector constructs and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3425505